LEADERSHIP TEAM

Mevion has benefited from Dr. Lawrence Tian’s leadership as a member of the board of directors since 2015 and was appointed Chairman in 2018. Dr. Tian brings a wealth of experience from the life sciences and medical device industry to this role. He is a Founding Partner of YuanMing Capital, a leading private equity firm which focuses on the investment in pharmaceutical research and development, innovative medical devices and high-end medical services in both China and the United States. He also serves as the Chairman of Investment Committee of China Pharmaceutical Industry Research and Development Association, and he is a member of the Biotech Advisory Panel of the Stock Exchange of Hong Kong Limited.

Dr. Tian also brings experience networking business leaders to the Mevion leadership team. He is the founder and Chairman of the China Entrepreneurs Forum, the most influential business owners association in China, and is the founder of the China-U.S. Business Leaders Roundtable, a prestigious cross-border communication platform.

Prior to Mevion, Dr. Tian has had successful career as a serial entrepreneur with a strong track record of success. In the financial markets, he founded China International Futures Co., Ltd. (CIFCO) in 1992. CIFCO grew into a leading brokerage firm and achieved the largest market share in China during his chairmanship. He also co-founded Wumart Group in 1994, which is currently the largest supermarket chain in Northern China.

Dr. Tian obtained his master’s degree and doctoral degree from Wuhan University. He received the China Economics Theory Innovation Award, China’s highest prize for economics. 

Dr. Tina Tianning Yu is the Chief Executive Officer and President of Mevion Medical Systems, the leader in compact proton therapy. With over 20 years of experience in life sciences, healthcare, and finance, Dr. Yu brings a unique blend of scientific expertise and business acumen to advancing cancer care.

Prior to Mevion, she was a Co-Founding Partner of YuanMing Capital, leading investments in successful biotech companies, including BeiGene and Ascentage Pharmaceuticals. Her career includes financial experience at institutions such as Vision Capital, Fidelity Asia Ventures, Morgan Stanley and Genzyme Biopharma, as well as scientific positions at Wyeth BioPharma.

Under Dr. Yu’s leadership, Mevion has achieved significant global growth and strong financial performance, becoming the preferred proton therapy provider for more NCI-Designated Comprehensive Cancer Centers. She led the development of the groundbreaking MEVION S250-FIT, the first proton therapy system designed for existing LINAC vaults. This system significantly reduces proton therapy’s size and complexity, enabling any health systems to bring proton therapy and benefit more patients.

Dr. Yu is a member of the CEOs Against Cancer - New England Chapter and was named to the Worcester Business Journal’s “Power 50” list. She is also a Regional Director with the Harvard Business School Healthcare Alumni Association. She holds a Ph.D. in Chemistry from Princeton, an MBA from Harvard, and a B.S. in Biology from the University of Science
and Technology of China.

Curt Kienast has been a pivotal leader at Mevion since 2007, driving its evolution into the global leader in compact proton therapy. With a background in the defense and healthcare industries, Curt joined Mevion as Director of Software Quality, advancing through key leadership roles in quality, engineering, service, and manufacturing. His strategic vision and operational expertise have been instrumental in streamlining manufacturing processes and delivering cutting-edge solutions. As Chief Operating Officer, Curt oversees Mevion’s operations, ensuring excellence in innovation, delivery, and service. He holds a Bachelor of Science in Computer Engineering from Embry-Riddle Aeronautical University.

Mark Jones serves as the Chief Technology Officer at Mevion Medical Systems, where he drives the innovation behind the development of revolutionary compact proton therapy solutions. With over four decades of engineering experience, he joined Mevion in 2006 and previously held the role of Vice President of Engineering. In that capacity, he was instrumental in developing key innovations such as the superconducting magnet and RF accelerator systems at the heart of Mevion’s technology, leading the teams responsible. Prior to joining Mevion, Mark held engineering leadership positions at Analogic Corporation, XRE Corporation, and Affymetrix, earning fifteen patents in proton therapy, medical imaging, and diagnostics. He holds a Bachelor of Science in Mechanical Engineering from Norwich University and a Master of Science in Engineering Management from Tufts University.

Dr. Lionel Bouchet has been instrumental in shaping the field of proton therapy center development since joining Mevion in 2006. Leading Mevion’s commercial team, and with expertise in partnering with healthcare systems, Lionel has spearheaded the development of Mevion’s proton therapy centers worldwide, positioning him as a global authority on compact proton therapy. Previously, Lionel served as Vice President of Technology Development for a pioneering group that commercialized image-guided radiotherapy systems later acquired by Varian Medical Systems, where he oversaw global clinical deployments. He holds an Engineering Degree from the École Nationale Supérieure de Physique de Grenoble, an M.S. in Nuclear Engineering from Texas A&M University, and a Ph.D. in Medical Health Physics from the University of Florida.

Dr. Skip Rosenthal brings over 30 years of expertise in radiation oncology and proton therapy. Drawing from his proton therapy leadership at the Harvard Cyclotron Laboratory and Massachusetts General Hospital, Skip has been instrumental in developing Mevion’s advanced clinical workflow, ensuring high-quality, patient-centered care. He leads the creation of customer education and training programs, leveraging his background as a senior medical physicist and assistant professor at Harvard Medical School. Skip is board-certified in therapeutic radiologic physics and holds a Ph.D. in Physics from Brandeis University, making him a pivotal figure in advancing proton therapy excellence.

Ping Hu has been a key member of Mevion’s leadership team since 2019, leading the company’s legal, compliance, regulatory, and quality functions and helping drive operational excellence throughout the organization. He also leads commercial development in international markets, supporting Mevion’s global growth strategy. Ping works closely with clinical and business leaders to advance Mevion’s mission and strategic priorities. With a unique combination of engineering experience in the high-tech industry and more than a decade of legal practice at national and international law firms, he brings deep expertise in navigating complex global matters. He holds a B.S. from Fudan University, an M.S. from Dartmouth College, and a J.D., summa cum laude, from Suffolk University Law School.

Dr. Townsend Zwart is a principal architect of the MEVION S250 Series proton accelerators and has been pivotal to Mevion’s innovation since 2005. He played a key role in designing the world’s first compact 250 MeV superconducting synchrocyclotron, earning multiple patents for his work in accelerator technology and pencil beam scanning. His groundbreaking contributions have advanced proton therapy, making treatments more precise and accessible. Prior to Mevion, Dr. Zwart contributed to proton therapy advancements at the Harvard Cyclotron Laboratory and spent over a decade at MIT as a Research Scientist, developing cutting-edge accelerator systems. He holds an AB in Physics from Dartmouth College and a Ph.D. in Applied Physics from Boston University.

Sandra Rousselle has been a driving force behind Mevion’s dynamic and collaborative workplace since joining in 2018. With over 25 years of global human resource experience, Sandra excels in fostering leadership, building strong teams, and implementing programs that enhance employee engagement and development. Her efforts have been instrumental in aligning organizational goals with a positive employee experience. Sandra also advances Mevion’s vision in public affairs, creating meaningful connections with surrounding communities. Before Mevion, she held leadership roles at Advanced Instruments LLC, Fresenius Medical Care, and Hollingsworth & Vose Company. A certified SPHR and SHRM-SCP, Sandra has contributed as a Subject Matter Expert for the Human Resources Certification Institute (HRCI).

Dr. Bin Zhao leads strategic manufacturing growth at Mevion through expert lean operations, supply chain optimization, and cross-functional collaboration. With a proven record of boosting production capacity, he translates vision into tactical execution to achieve rapid top-line growth. Dr. Zhao oversees manufacturing engineering, production, and supply chain while ensuring consistent regulatory compliance. Before joining Mevion, he drove significant efficiency improvements and cost reductions at premier organizations, integrating advanced technologies and ERP solutions. He excels in delivering projects on time and on budget while cultivating high-performing teams. Dr. Zhao earned his Ph.D. in Materials Science and an Executive MBA, reflecting a commitment to both technical and business excellence.

Ying Xiong brings nearly 25 years of experience in research, development, and product management to Mevion Medical Systems, driving the creation of high-quality, innovative radiation therapy solutions. At Mevion, Ying leads the development of cutting-edge products and fosters clinical collaborations to advance proton therapy. Before joining Mevion in 2019, she served as Director of Product Strategy at Accuray, where she shaped software roadmaps for Radixact, TomoTherapy, and CyberKnife. During her time at Philips Radiation Oncology Systems, Ying played a key role in advancing the Pinnacle treatment planning system. She holds a Master of Science in Applied Mathematics from Stony Brook University (State University of New York) and a Bachelor of Science in Applied Mathematics from Shanghai Jiaotong University.

Robyn Walker leads the Customer Success team at Mevion Medical Systems, ensuring the successful implementation and utilization of Mevion’s proton therapy systems. With over 20 years of experience in radiation oncology, including a decade as Chief Radiation Therapist at Duke University’s Cancer Institute, Robyn brings a deep understanding of clinical operations and a strong focus on customer satisfaction. At Mevion, she oversees all aspects of Customer Success, from Site Planning and Solutions, Installation and Beam Commissioning, Clinical Readiness and Training, Service, and Product Support. Prior to joining Mevion, Robyn held leadership roles at Varian Medical Systems and Vision RT. A published author and respected thought leader, Robyn leverages her extensive clinical and technical expertise to educate audiences and drive the successful adoption of advanced radiation therapy technologies.